SNT-4288 / Sonata Therap - LARVOL DELTA

Sonata Therapeutics Announces Presentations Supporting its Network Medicines Approach at SITC 2023 (Businesswire) - "Sonata Therapeutics, Inc...announced it will be presenting three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting....One of the poster presentations will highlight one of Sonata’s Network Medicines, iART, that reprograms diseased cells to become the coordinators of cure for various indications including cancer....The second poster presentation will highlight how SNT-20109, one of Sonata’s lead oncology programs, can induce protective immunity and an innovative form of enhanced-immunogenic cell death that has never been characterized in murine cancer models. The third poster presentation will highlight SNT-4288, another of Sonata’s lead oncology programs, as a novel tool to induce ferroptosis for the treatment of sarcoma."

Preclinical • Oncology • Sarcoma • Solid Tumor